TrialPloS one2021

A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers.

George F Wohlford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.